A Self‐Augmenting Ion‐ROS Nanogenerator for Deep‐Penetration Pyroptosis‐Driven Immunotherapy of Solid Tumors
Source abstract
Abstract
ABSTRACT Pyroptosis holds significant potential for cancer immunotherapy by coupling tumor eradication with immune activation. However, its efficacy remains limited due to poor penetration of pyroptosis inducers and insufficient activation within tumors, primarily caused by dense extracellular matrix and elevated tumor interstitial fluid pressure (TIFP). To address these challenges, an acid‐responsive nanogenerator (CPFH) that co‐delivers Ca 2+ and reactive oxygen species (ROS) was developed to simultaneously enhance both penetration and pyroptosis induction. The nanogenerator integrates a calcium peroxide (CaO 2 ) core with a pH‐degradable polydopamine layer, Fe‐doped polyoxometalate (Fe‐POM) clusters, and hyaluronic acid (HA) targeting ligands. In the acidic tumor microenvironment (TME), CPFH releases Ca 2+ and H 2 O 2 , which initiates caspase‐3/gasdermin E (GSDME)‐mediated pyroptosis via Ca 2+ overload while also reducing TIFP through water depletion. Simultaneously, Fe‐POM catalyzes hydroxyl radical (•OH) generation via Fenton reaction and provides second near‐infrared (NIR‐II) photothermal effects, enhancing oxidative stress, disrupting mitochondrial function, and alleviating solid stress through collagen degradation. This self‐reinforcing Ca 2+ /ROS cycle amplifies GSDME activation and improves nanoparticle penetration. Consequently, robust immunogenic cell death occurs with damage‐associated molecular patterns (DAMPs) release, dendritic cell maturation, and cytotoxic T cell infiltration. In vivo, CPFH treatment achieved near‐complete tumor regression with minimal toxicity, demonstrating strong potential for solid tumor immunotherapy.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Inflammasome and immune disorders
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
College of Pharmacy Key Laboratory of Innovative Drug Development and Evaluation Hebei Medical University Shijiazhuang China
National Key Laboratory of New Pharmaceutical Preparations and Excipients Hebei Medical University Shijiazhuang China
Department of General Surgery Tianjin First Central Hospital Tianjin China
Hebei Provincial Key Laboratory of Photoelectric Control on Surface and Interface College of Sciences Hebei University of Science and Technology Shijiazhuang China
References (58)
Show source-provided references
1. 10.1038/s41423‐022‐00905‐x10.1038/s41423‐022‐00905‐x ↗
2. 10.1038/s41565‐022‐01125‐010.1038/s41565‐022‐01125‐0 ↗
3. 10.1038/s41586‐020‐2079‐110.1038/s41586‐020‐2079‐1 ↗
4. 10.1016/j.cej.2024.15894410.1016/j.cej.2024.158944 ↗
5. 10.1021/acsnano.4c0151810.1021/acsnano.4c01518 ↗
6. 10.1016/j.cej.2022.14017510.1016/j.cej.2022.140175 ↗
7. 10.1186/s12951‐023‐02146‐010.1186/s12951‐023‐02146‐0 ↗
8. 10.1158/0008‐5472.CAN‐12‐452110.1158/0008‐5472.CAN‐12‐4521 ↗
9. 10.1080/1061186X.2024.236757910.1080/1061186X.2024.2367579 ↗
10. 10.1002/adhm.20240059610.1002/adhm.202400596 ↗
11. 10.1016/j.ijbiomac.2024.12964210.1016/j.ijbiomac.2024.129642 ↗
12. 10.1016/j.cis.2024.10312410.1016/j.cis.2024.103124 ↗
13. 10.1016/j.addr.2021.02.01910.1016/j.addr.2021.02.019 ↗
14. 10.1016/j.jconrel.2024.12.04810.1016/j.jconrel.2024.12.048 ↗
15. 10.1002/smll.20231096410.1002/smll.202310964 ↗
16. 10.3389/fonc.2015.0016510.3389/fonc.2015.00165 ↗
17. 10.1021/acsnano.1c0304810.1021/acsnano.1c03048 ↗
18. 10.1002/smtd.20240209110.1002/smtd.202402091 ↗
19. 10.1021/acsami.2c1120010.1021/acsami.2c11200 ↗
20. 10.1002/anie.20220490410.1002/anie.202204904 ↗
21. 10.1021/acsnano.4c0001710.1021/acsnano.4c00017 ↗
22. 10.1016/j.actbio.2021.10.01610.1016/j.actbio.2021.10.016 ↗
23. 10.1016/j.jcis.2024.01.21710.1016/j.jcis.2024.01.217 ↗
24. 10.3389/fimmu.2024.137899010.3389/fimmu.2024.1378990 ↗
25. 10.1002/adfm.20210024310.1002/adfm.202100243 ↗
26. 10.1002/adhm.20200000510.1002/adhm.202000005 ↗
27. 10.1002/adfm.20240269210.1002/adfm.202402692 ↗
28. 10.1039/D4CC03445G10.1039/D4CC03445G ↗
29. 10.1016/j.biomaterials.2023.12233210.1016/j.biomaterials.2023.122332 ↗
30. 10.1186/s40164‐020‐00192‐010.1186/s40164‐020‐00192‐0 ↗
31. 10.1002/smll.20190211810.1002/smll.201902118 ↗
32. 10.1016/j.cej.2022.13886410.1016/j.cej.2022.138864 ↗
33. 10.1002/smll.20240545710.1002/smll.202405457 ↗
34. 10.1039/C8TB03331E10.1039/C8TB03331E ↗
35. 10.1016/j.snb.2024.13535810.1016/j.snb.2024.135358 ↗
36. 10.1002/adma.20230343210.1002/adma.202303432 ↗
37. 10.1002/anie.20230186610.1002/anie.202301866 ↗
38. 10.1021/acsnano.8b0605810.1021/acsnano.8b06058 ↗
39. 10.1039/d3cs00087g10.1039/d3cs00087g ↗
40. 10.1002/smll.20240925010.1002/smll.202409250 ↗
41. 10.1021/acsnano.5c0192210.1021/acsnano.5c01922 ↗
42. 10.1002/anie.20230225510.1002/anie.202302255 ↗
43. 10.1002/adma.20230409810.1002/adma.202304098 ↗
44. 10.1002/advs.20240352010.1002/advs.202403520 ↗
45. 10.1016/j.cej.2024.14948510.1016/j.cej.2024.149485 ↗
46. 10.1002/advs.20250556710.1002/advs.202505567 ↗
47. 10.1016/j.jconrel.2024.01.04510.1016/j.jconrel.2024.01.045 ↗
48. 10.1016/j.jare.2025.01.04210.1016/j.jare.2025.01.042 ↗
49. 10.1002/adfm.20240049610.1002/adfm.202400496 ↗
50. 10.1021/acssuschemeng.2c0200610.1021/acssuschemeng.2c02006 ↗
51. 10.1002/adhm.20250391410.1002/adhm.202503914 ↗
52. 10.1002/advs.20220745610.1002/advs.202207456 ↗
53. 10.1002/advs.202310.1002/advs.2023 ↗
54. 10.1002/advs.20240048510.1002/advs.202400485 ↗
55. 10.1016/j.nantod.2022.10172710.1016/j.nantod.2022.101727 ↗
56. 10.1002/adfm.20231478010.1002/adfm.202314780 ↗
57. 10.1016/j.jconrel.2024.01.02110.1016/j.jconrel.2024.01.021 ↗
58. 10.1021/acsnano.4c0869010.1021/acsnano.4c08690 ↗